News & Events

BRCA1/2-mutated tumor cells often survive treatment, whether it’s chemo- or radiotherapy, because they can repair therapy-induced DNA damage. A team led by Claus Scheidereit of the Max Delbrück Center has now reported in The EMBO Journal how blocking the TSG101 protein hinders these tumor cells from carrying out repair processes.

A new therapeutic agent may offer hope to young people suffering from a severe form of muscle cancer. As a research team led by Anton Henssen reports in “Nature Communications”, this agent prevents the repair of DNA damage in cancer cells, ultimately causing their death.

If a secretion in the lungs’ alveoli is not cleared regularly, breathing difficulties can develop. In a study published in Science Immunology, a team led by Alexander Mildner and Achim Leutz has now explained the pivotal role of the transcription factor C/EBPb in this process.

And a celebration it was: After two years of virtual graduation ceremonies due to Covid-19, doctoral students at the Max Delbrück Center were once again able to receive their graduation certificates live on stage.

The newly appointed scientific director of the Max Delbrück Center is recognized for her pioneering stem cell work in diabetes. Her team studies the development and function of insulin-producing beta cells and aims to generate beta cells from stem cells, paving the way for therapeutic applications.

MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previously incurable muscle diseases using its innovative muscle stem cell technology.

Defective mitochondrial can lead to neurodegenerative and muscular diseases. But how does the “powerhouse” of the cell normally maintain its characteristic shape? In Science Advances, new molecular insights have now been provided by an MDC team led by Oliver Daumke.